DCM
CCCC icon

Driehaus Capital Management’s C4 Therapeutics CCCC Stock Holding History

Driehaus Capital Management’s Portfolio CCCC Stock Details CCCC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-345,969
Closed -$2.04M – 393
2022
Q4 		$2.04M Sell
345,969
-260,752
-43% -$2.16M 0.03% 292
2022
Q3 		$5.32M Buy
606,721
+9,347
+2% +$97K 0.08% 265
2022
Q2 		$4.5M Buy
597,374
+243,462
+69% +$2.14M 0.07% 281
2022
Q1 		$8.59M Sell
353,912
-6,798
-2% -$165K 0.11% 250
2021
Q4 		$11.6M Sell
360,710
-280,689
-44% -$11.1M 0.12% 225
2021
Q3 		$28.7M Buy
641,399
+433,816
+209% +$18.6M 0.34% 88
2021
Q2 		$7.86M Buy
+207,583
New +$7.43M 0.1% 247

Other funds holding CCCC

ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Driehaus Capital Management's CCCC Position: Q1 2023 in Review

Driehaus Capital Management sold out of C4 Therapeutics (CCCC) in Q1 2023, closing a stake of 345,969 shares — an estimated $2.04M sold.

Driehaus Capital Management first reported a position in CCCC in Q2 2021 and held it in 7 quarters. The position peaked at $28.7M in Q3 2021. 120 funds tracked by Wall St. Rank hold CCCC as of Q1 2023.

  • Driehaus Capital Management reported no remaining C4 Therapeutics position as of Q1 2023 after selling out during the quarter.
  • Driehaus Capital Management sold 345,969 C4 Therapeutics shares in Q1 2023, an estimated $2.04M.
  • Driehaus Capital Management first reported a position in C4 Therapeutics in Q2 2021 and held it in 7 quarters.
  • Driehaus Capital Management's C4 Therapeutics position peaked at $28.7M in Q3 2021.
  • 120 funds tracked by Wall St. Rank held C4 Therapeutics as of Q1 2023.

Based on Driehaus Capital Management's 13F filing for Q1 2023, filed 15 May 2023.